Abstract
To the Editor: Rituximab is a chimeric anti-CD20 monoclonal antibody that has been approved for the treatment of lymphoma and rheumatoid arthritis. It also has been used in a variety of autoimmune diseases. However, rituximab has seldom been used to treat psoriasis because the disease is mainly T-cell and macrophage-driven, rather than antibody-mediated.1 Herein, we describe a case of palmoplantar pustulosis, a less severe and localized variant of pustular psoriasis, with treatment failure after tumor necrosis factor–alfa blockade but dramatic improvement after rituximab treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
